Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs
Bimazubute, M.; Cambier, Carole; Baert, K.et al.
2010 • In Journal of Veterinary Pharmacology and Therapeutics, 33 (2), p. 183-188
[en] The pharmacokinetic behaviour of enrofloxacin (ENRO) in plasma and nasal secretions of healthy pigs was investigated, after a single-dose intramuscular administration of 2.5 mg/kg body weight of the drug. Blood samples and nasal secretions were collected at predetermined times after drug administration. Concentrations of ENRO and its active metabolite ciprofloxacin (CIPRO) were determined in plasma and nasal secretions by high-performance liquid chromatography (HPLC). CIPRO was not detected probably because we investigated young weaned pigs. The data collected in 12 pigs for ENRO were subjected to noncompartmental analysis. In plasma, the maximum concentration of drug (C-max), the time at which this maximum concentration of drug (T-max) was reached, the elimination half-life (t(beta)(1/2)) and the area under the concentration vs. time curve (AUC) were, respectively, 694.7 ng/mL, 1.0 h, 9.3 h and 8903.2 ng h/mL. In nasal secretions, Cmax, Tmax, t(beta)(1/2) and AUC were, respectively, 871.4 ng/mL, 2.0 h, 12.5 h and 11 198.5 ng.h/mL. In a second experiment conducted in 10 piglets, the relationship between concentrations of ENRO measured in the plasma and the nasal secretions has been determined following single-dose intramuscular administration of 2.5, 10 or 20 mg/kg body weight of the drug. It has been demonstrated that, among several variables, i.e., (1) the dose administered, (2) the time between intramuscular injection and blood sampling, (3) the age, (4) the sex, (5) the animal body weight and (6) the plasma concentration of the drug, only the latter influenced significantly the ENRO concentration in nasal secretions. Practically, using a generalized linear mixed model, ENRO concentrations in the nasal secretions (mu g/mL) can be predicted taking into account the ENRO concentrations in plasma (mu g/mL), according to the following equation: ENROnasal secretion 1.94 ENROplasma - 0.24.
Disciplines :
Pharmacy, pharmacology & toxicology Veterinary medicine & animal health
Author, co-author :
Bimazubute, M.
Cambier, Carole ; Université de Liège - ULiège > Département de sciences fonctionnelles > Pharmacologie, pharmacothérapie et toxicologie - Département de sciences fonctionnelles
Baert, K.
Vanbelle, Sophie ; Université de Liège - ULiège > Département de mathématique > Département de mathématique
Chiap, Patrice ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique - Département de mathématique
Delporte, Jean-Pierre ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Gustin, Pascal ; Université de Liège - ULiège > Département de sciences fonctionnelles > Pharmacologie, pharmacothérapie et toxicologie
Language :
English
Title :
Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs
Publication date :
2010
Journal title :
Journal of Veterinary Pharmacology and Therapeutics
Aarestrup, F.M., Oliver Duran, C. & Burch, D.G.S. (2008) Antimicrobial resistance in swine production. Animal Health Research Reviews, 9, 135-148.
Agersø, H. & Friis, C. (1998) Penetration of amoxycillin into the respiratory tract tissues and secretions in pigs. Research in Veterinary Sciences, 64, 245-250.
Anadón, A., Martinez-Larrañaga, M.R., Diaz, M.J., Fernandez, R., Martinez, M.A. & Fernandez, M.C. (1995) Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. Journal of Veterinary Pharmacology and Therapeutics, 18, 220-225.
Anadón, A., Martínez-Larrañaga, M.R., Díaz, M.J., Fernández-Cruz, M.L., Martínez, M.A., Frejo, M.T., Mart́nez, M., Iturbe, J. & Tafur, M. (1999) Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. American Journal of Veterinary Research, 60, 1377-1382.
Bimazubute, M., Rozet, E., Dizier, I., Gustin, P., Hubert, P., Crommen, J. & Chiap, P. (2008) Liquid chromatographic determination of enrofloxacin in nasal secretions and plasma of healthy pigs using restricted access material for on-line sample clean-up. Journal of Chromatography. A., 1189, 456-466.
Cox, S.K., Cottrell, M.B., Smith, L., Papich, M.G., Frazier, D.L. & Bartges, J. (2004) Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species. Journal of Veterinary Pharmacology and Therapeutics, 27, 139-146.
Davis, J.L., Foster, D.M. & Papich, M.G. (2007) Pharmacokinetics and tissue distribution of enrfloxacin and its active metabolite ciprofloxacin in calves. Journal of Veterinary Pharmacology and Therapeutics, 30, 564-571.
Friis, C. (1993) Penetration of danofloxacin into the respiratory tract tissues and secretions in calves. American Journal of Veterinary Research, 54, 1122-1127.
Kadlec, K., Kehrenberg, C., Wallmann, J. & Schwarz, S. (2004) Antimicrobial susceptibility of Bordetella bronchiseptica isolates from porcine respiratory tract infections. Antimicrobial agents and Chemotherapy, 48, 4903-4906.
Küng, K., Riond, J.L. & Wanner, M. (1993) Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. Journal of Veterinary Pharmacology and Therapeutics, 16, 462-468.
Lizarazo, Y.A., Ferri, E.F., de la Fuente, A.J. & Martín, C.B. (2006) Evaluation of changes in antimicrobial susceptibility patterns of Pasteurella multocida subsp multocida isolates from pigs in Spain in 1987-1988 and 2003-2004. American Journal of Veterinary Research, 67, 663-668.
Papich, M.G. & Rivière, J.E. (2001) Fluoroquinolone antimicrobial drugs. In Veterinary Pharmacology and Therapeutics, 8th edn. Ed. Adams, R., Chapter 45, pp. 898-917. Iowa State University Press, Ames.
Pijpers, A., Heinen, E., De Jong, A. & Verheijden, J.H.M. (1997) Enrofloxacin pharmacokinetics after intravenous and intramuscular administration in pig. Journal of Veterinary Pharmacology and Therapeutics, 20, 42-43.
Post, L.O., Cope, C.V., Farrell, D.E., Baker, J.D. & Myers, M.J. (2002) Influence of porcine Actinobacillus pleuropneumoniae infection and dexamethasone on the pharmacokinetic parameters of enrofloxacin. The Journal of Pharmacology and Experimental Therapeutics, 301, 217-222.
Richez, P., Pedersen Mörner, A., De Jong, A. & Monlouis, J.D. (1997) Plasma pharmacokinetics of parenterally administered danofloxacin and enrofloxacin in pigs. Journal of Veterinary Pharmacology and Therapeutics, 20, 41-42.
Villa, R., Prandini, E., Caloni, F. & Carli, S. (1997) Serum protein binding of some sulfonamides, quinolones and fluoroquinolones in farm and domestic animals. Journal of Veterinary Pharmacology and Therapeutics, 20 (Suppl. 1), 34-35.
Walker, R.D. & Dowling, P.M. (2006) Fluoroquinolones. In Antimicrobial Therapy in Veterinary Medicine, 4th edn. Eds Giguère, S., Prescott, J.F., Baggot, J.D., Walker, R.D. & Dowling, P.M., Chapter 17, pp. 263-284. Iowa State University Press, Ames.
Wallmann, J., Kaspar, H. & Kroker, R. (2004) Data on the prevalence of antimicrobial susceptibility of veterinary pathogens from cattle and pigs: national antibiotic resistance monitoring 2002 ? 2003 of the BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Berlin). Berliner und Münchener Tierärztliche Wochenschrift, 117, 480-492.
Wiuff, C., Lykkesfeldt, J., Aarestrup, F.M. & Svendsen, O. (2002) Distribution of enrofloxacin in intestinal tissue and contents of healthy pigs after oral and intramuscular administrations. Journal of Veterinary Pharmacology and Therapeutics, 25, 335-342.
Zeng, Z. & Fung, K. (1997) Effects of experimentally induced Escherichia coli infection on the pharmacokinetics of enrofloxacin in pigs. Journal of Veterinary Pharmacology and Therapeutics, 20 (Suppl. 1), 39.
